A Bayesian Re-Analysis of the GALFLU Trial of high dose versus standard dose influenza vaccine against hospitalisation outcomes.

Authors

Jacobo Pardo-Seco, Carmen Rodriguez-Tenreiro-Sánchez, Iago Giné-Vázquez, Narmeen Mallah, Susana Mirás-Carballal, Marta Piñeiro-Sotelo, Martín Cribeiro González, Mónica Conde Pájaro, Juan-Manuel González-Pérez, Irene Rivero-Calle, Xabier Bello, Josefina L Razzini, Antonio Salas, Rebecca C Harris, Matthew M Loiacono, Robertus van Aalst, Manel Farre, Marine Dufournet, Niklas Dyrby Johansen, Daniel Modin, Tor Biering-Sørensen, Carmen Duran-Parrondo, Federico Martinón-Torres

Published in

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Aug 03, 2026. Epub Aug 03, 2026.

Abstract

The GALFLU trial showed a lower incidence of hospitalisation among adults aged 65-79 years randomised to high-dose inactivated influenza vaccine (HD-IIV) compared with standard-dose inactivated influenza vaccine (SD-IIV). This Bayesian re-analysis estimated an >80% probability of benefit (rVE >10%) against influenza-or-pneumonia-related hospitalisation, supporting the benefit of HD-IIV over SD-IIV.

PMID:
42546169
Bibliographic data and abstract were imported from PubMed on 04 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.